Citations

Clear

5 citation(s) found for "Friedman, Mark".

Appetite Suppression by GLP ‐1 Receptor Agonists: Role of Delayed Gastric Emptying
Friedman, Mark I. , Harmsen, W. Scott, Camilleri, Michael

Mayo Clinic

Obesity | July 2, 2026 | Volume: 34 | Issue: 8 | Pages: 1535-1540

10.1002/oby.70255 | PMID 42392577 Get It

ABSTRACT Objective This study aimed to evaluate relationships between delayed gastric emptying and appetite suppression during treatment with liraglutide, a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA). Methods We conducted a secondary data analysis from a 16‐week randomized, placebo‐controlled liraglutide trial in patients with obesity. We examined correlations between solid food gastric emptying and measurements of satiation and energy intake in the entire cohorts at baseline and end of treatment and separately in placebo‐ and liraglutide‐treated patients who completed the trial. We also compared appetitive measures among liraglutide‐treated participants who displayed either normal, persistently delayed, or transiently delayed emptying during treatment. Results In the entire cohorts at baseline and completion, gastric emptying correlated significantly with energy intake and, at baseline, with one parameter of satiation. Gastric emptying accounted for only 4%–6% of the variance in these appetitive measures. No such correlations were found in the placebo‐ or liraglutide‐treated groups alone. There were no differences in appetitive measures among the subgroups that displayed different gastric emptying patterns during liraglutide treatment. Conclusions Delayed gastric emptying appears to play little direct role in appetite suppression induced by liraglutide. Further research should explore whether delayed emptying or other gastrointestinal effects of other GLP‐1RAs affect appetite directly or indirectly. Trial Registration: ClinicalTrials.gov identifier: NCT02647944
NCCN Guidelines® Insights: Colorectal Cancer Screening, Version 1.2024
Llor, Xavier , Abbass, Mohammad Ali , Chen, Christopher T. , Cooper, Gregory S. , Early, Dayna S., Friedman, Mark , Fudman, David , Giardiello, Francis M., Glaser, Kathryn , Gurudu, S, Hall, Michael J. , Issaka, Rachel B. , Kidambi, Trilokesh D. , Lazenby, Audrey J., Maratt, Jennifer K. , Markowitz, Arnold J. , Marsano, Joseph, Olortegui, Kinga Skowron , Peter, Shajan , Porter, Laura , Shafi, Mehnaz, Terdiman, Jonathan P., Vu, Peter , Wood, Elizabeth H., Cassara, Carly J., Gurudu, Surya, Ness, Reid M. , Bishu, Shrinivas , Huang, Lyen C. , Katona, Bryson W , May, Folasade P. , Mayer, Robert J. , Olortegui, Kinga S. , Patel, Swati , Stanich, Peter P. , Weiss, Jennifer M. , Wood, Elizabeth, Sambandam, Vaishnavi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 5, 2024 | Volume: 22 | Issue: 7 | Pages: 438-446

10.6004/jnccn.2024.0047 | PMID 39236750 Get It

The NCCN Guidelines for Colorectal Cancer (CRC) Screening describe various colorectal screening modalities as well as recommended screening schedules for patients at average or increased risk of developing sporadic CRC. They are intended to aid physicians with clinical decision-making regarding CRC screening for patients without defined genetic syndromes. These NCCN Guidelines Insights focus on select recent updates to the NCCN Guidelines, including a section on primary and secondary CRC prevention, and provide context for the panel’s recommendations regarding the age at which to initiate screening in average-risk individuals and those with increased risk based on personal history of childhood, adolescent, and young adult cancer.
The significance of histological activity measurements in immune checkpoint inhibitor colitis
Pai, Rish K. , Pai, Reetesh K., Pai, Reetesh K., Brown, Ian , Choi, Won‐Tak , Kumarasinghe, M. Priyanthi , Gunawardena, Dilini , Kim, Baek Hui, Friedman, Mark , Ghayouri, Masoumeh, Lauwers, Gregory Y. , Brown, Ian S , Pai, Reetesh K., Pai, Reetesh K., Schaeffer, David F. , Farnell, David

Mayo Clinic

Alimentary Pharmacology & Therapeutics | September 3, 2023 | Volume: 53 | Issue: 1 | Pages: 150-159

10.1111/apt.16142 | PMID 33146440 Get It

SummaryBackgroundColitis is a significant complication of immune checkpoint inhibitors (ICI). Currently, clinical and endoscopic severity are used to guide therapy.AimsTo investigate associations between clinical, endoscopic, and histological features with outcomesMethodsWe identified 149 patients from seven institutions with biopsy‐proven ICI colitis. Biopsies were evaluated for histological features including the Geboes score, and the Robarts histopathological index (RHI) was calculated. Clinical, endoscopic, and histological data were tested for associations with biological use and adverse colitis outcomes (biological‐refractory colitis, colectomy or death from colitis).ResultsThree mutually exclusive histological patterns were identified: acute colitis, chronic active colitis and microscopic colitis. Microscopic colitis was associated with older age (68.5 vs 61 years for acute colitis pattern, P = 0.02) and longer time to colitis (5.5 vs 3 months for the other patterns, P = 0.05). Biological use was associated with earlier time to colitis (2 vs 3 months, P = 0.04) and higher RHI (18 vs 12, P = 0.007). On multivariate analysis, RHI ≥14 was associated with biological use with an odds ratio of 4.5 (95% CI 1.4‐13.8; P = 0.01). Adverse colitis outcomes were associated with shorter time to colitis (2 vs 3 months, P = 0.008) and higher RHI (24 vs 14, P = 0.001). On multivariate analysis, RHI ≥24 was associated with adverse colitis outcomes with an odds ratio 9.5 (95% CI 2.1‐42.3 P = 0.003).ConclusionHistological activity as measured by RHI is the only factor independently associated with biological use and adverse colitis outcomes. Prospective studies are needed to validate these findings to determine if histological activity should be incorporated into therapeutic algorithms.
NCCN Guidelines Insights: Colorectal Cancer Screening, Version 2.2020
Provenzale, Dawn, Llor, Xavier , Abbadessa, Benjamin, Cooper, Gregory S. , Early, Dayna S., Friedman, Mark , Giardiello, Francis M., Glaser, Kathryn , Gurudu, Suryakanth, Halverson, Amy L. , Issaka, Rachel B. , Jain, Rishi , Kidambi, Trilokesh D. , Lazenby, Audrey J., Markowitz, Arnold J. , May, Folasade P. , Mehta, Shivan J. , Peter, Shajan , Stanich, Peter P. , Terdiman, Jonathan P., Keller, Jennifer , Dwyer, Mary A., Ogba, Ndiya , Ness, Reid M. , Weiss, Jennifer M. , Kanth, Priyanka , Maguire, Lillias Holmes , Mayer, Robert J. , Patel, Swati

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 6, 2020 | Volume: 18 | Issue: 10 | Pages: 1312-1320

10.6004/jnccn.2020.0048 | PMID 33022639 Get It

The NCCN Guidelines for Colorectal Cancer (CRC) Screening describe various colorectal screening modalities as well as recommended screening schedules for patients at average or increased risk of developing sporadic CRC. They are intended to aid physicians with clinical decision-making regarding CRC screening for patients without defined genetic syndromes. These NCCN Guidelines Insights focus on select recent updates to the NCCN Guidelines, including a section on primary and secondary CRC prevention, and provide context for the panel’s recommendations regarding the age to initiate screening in average risk individuals and follow-up for low-risk adenomas.
Preoperative Risk Stratification of Right Ventricular Function Utilizing Cardiac Magnetic Resonance Imaging Compared With Echocardiographic and Hemodynamic Parameters
Avery, Ryan , Ebong, Imo , Skaria, Rinku , Day, Kevin, Miller, Christopher , Juneman, Elizabeth , Oliva, Isabel, Friedman, Mark J., Maltais, Simon, Khalpey, Zain , Miller, Christopher

Mayo Clinic

ASAIO Journal | July 21, 2019 | Volume: 66 | Issue: 5 | Pages: 547-552

10.1097/mat.0000000000001046 | PMID 31335372 Get It

Accurate right ventricle functional analysis prior to mechanical circulatory support continues to be valuable for preoperative stratification of patients at risk for developing right ventricular (RV) failure. While cardiac magnetic resonance imaging (CMR) remains the gold standard, CMR is limited by availability and patient-specific contraindications. Further investigation of other imaging modalities would be beneficial as it may serve as a surrogate to identifying RV systolic dysfunction. A single-center, retrospective study including 29 patients with advanced heart failure was performed. All patients underwent ventricular functional analysis with both CMR and echocardiography, and 19 patients underwent right heart catheterization. Predictability with multimodal assessment of RV function was determined using logistic regression methods. Of the 29 participants, 10 had severe RV dysfunction. Tricuspid annular plane of systolic excursion was a modest predictor of RV dysfunction with odd ratio (OR) of 0.07 (0.01–0.72) and c-statistic of 0.79. Invasive hemodynamic measurement of cardiac index by thermodilution method was also predictive of RV dysfunction but failed to reach statistical significance (OR of 0.03, <0.001–1.28) with c-statistic of 0.83. The role of invasive hemodynamic data in predicting RV function compared with CMR should be further explored among patients with advanced heart failure.